Ibex Wealth Advisors boosted its stake in Allergan PLC. (NYSE:AGN) by 4.7% during the first quarter, Holdings Channel reports. The firm owned 2,630 shares of the company’s stock after buying an additional 118 shares during the period. Ibex Wealth Advisors’ holdings in Allergan PLC. were worth $625,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Crestwood Advisors Group LLC purchased a new position in Allergan PLC. during the first quarter valued at approximately $103,000. Feltz Wealth PLAN Inc. purchased a new position in Allergan PLC. during the first quarter valued at approximately $107,000. Enterprise Financial Services Corp boosted its position in Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock valued at $110,000 after buying an additional 178 shares during the period. JNBA Financial Advisors boosted its position in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares during the period. Finally, Webster Bank N. A. boosted its position in Allergan PLC. by 31.0% in the first quarter. Webster Bank N. A. now owns 520 shares of the company’s stock valued at $124,000 after buying an additional 123 shares during the period. Hedge funds and other institutional investors own 84.77% of the company’s stock.

Allergan PLC. (NYSE:AGN) traded down 1.14% on Thursday, reaching $235.26. 618,134 shares of the company’s stock traded hands. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80. The firm has a market cap of $78.86 billion, a price-to-earnings ratio of 7.17 and a beta of 1.16. The stock’s 50 day moving average is $246.68 and its 200 day moving average is $238.04.

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.25%. The firm had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. During the same quarter in the previous year, the firm posted $3.35 earnings per share. The business’s revenue was up 8.8% on a year-over-year basis. On average, equities research analysts predict that Allergan PLC. will post $16.25 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be paid a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a yield of 1.18%. The ex-dividend date is Wednesday, August 16th. Allergan PLC.’s payout ratio is currently 9.95%.

ILLEGAL ACTIVITY NOTICE: “Allergan PLC. (AGN) Stake Increased by Ibex Wealth Advisors” was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/allergan-plc-agn-stake-increased-by-ibex-wealth-advisors/1471034.html.

Several research firms have commented on AGN. UBS AG restated a “buy” rating and issued a $275.00 target price on shares of Allergan PLC. in a research report on Monday, May 15th. BidaskClub cut shares of Allergan PLC. from a “buy” rating to a “hold” rating in a research report on Wednesday. Wells Fargo & Company restated an “outperform” rating and issued a $280.00 target price (up previously from $270.00) on shares of Allergan PLC. in a research report on Wednesday. Mizuho reaffirmed a “buy” rating and issued a $267.00 price target on shares of Allergan PLC. in a research note on Wednesday, August 2nd. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and issued a $231.00 price target on shares of Allergan PLC. in a research note on Friday, July 14th. Eight analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $274.49.

In other Allergan PLC. news, Director Nesli Basgoz sold 1,889 shares of Allergan PLC. stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total value of $416,430.05. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.36% of the company’s stock.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.